Results 91 to 100 of about 63,312 (252)

A Case of Sarcomatoid Peritoneal Mesothelioma with Death due to Rapid Aggravation of Ascites [PDF]

open access: yes, 2010
A 70-year-old man with a history of doing wiring work for 30 years was admitted to our hospital because of lower abdominal pain and ascites. Four months before admission he underwent cholecystectomy due to cholelithiasis and cholecystitis.At that time ...
岩下, 明日香   +4 more
core   +1 more source

Malignant Mesothelioma [PDF]

open access: yes, 2012
This book brings together the knowledge of eminent experts in the field of malignant mesothelioma, a highly invasive tumor of mesothelium that is the protective lining covering several body cavities.

core   +2 more sources

CD93—An emerging vascular target in cancer therapy

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira   +3 more
wiley   +1 more source

Diagnosis and management of pleural mesothelioma: three unique cases and review of the literature

open access: yesBMC Pulmonary Medicine
Background Mesothelioma is a rare pleural tumor. Compared to diffuse pleural mesothelioma, localized pleural mesothelioma carries a better prognosis and may be managed with surgical resection.
Zeina Al Achkar   +2 more
doaj   +1 more source

MONITORING OF MESOTHELIOMA IN SOUTHERN BRAZIL: A SITUATION TO BE INVESTIGATED

open access: yesCogitare Enfermagem, 2017
Brazil is one of the world’s greatest producers of chrysotile, but the occurrence of mesothelioma is apparently low. However, identification of cases of mesothelioma is difficult due to errors of diagnosis and registries of deaths.
Francisco José Koller   +5 more
doaj   +1 more source

Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective

open access: yesBritish Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang   +4 more
wiley   +1 more source

Intercellular Communication in Malignant Pleural Mesothelioma: Properties of Tunneling Nanotubes

open access: yesFrontiers in Physiology, 2014
Malignant pleural mesothelioma is a particularly aggressive and locally invasive malignancy with a poor prognosis despite advances in understanding of cancer cell biology and development of new therapies.
Justin William Ady   +10 more
doaj   +1 more source

Integrative eQTL and Mendelian randomization analysis reveals key genetic markers in mesothelioma

open access: yesRespiratory Research
Background Mesothelioma is a rare cancer that originates from the pleura and peritoneum, with its incidence increasing due to asbestos exposure. Patients are frequently diagnosed at advanced stages, resulting in poor survival rates.
Jinsong Li   +4 more
doaj   +1 more source

Miliary Mesothelioma

open access: yesRespirology Case Reports
ABSTRACTMiliary spread of mesothelioma is a rare but important manifestation of late‐stage disease, likely due to hematogenous dissemination. This case highlights characteristic CT imaging findings, emphasizing the need for awareness among clinicians and radiologists.
Dujinthan Jayabalan   +4 more
openaire   +3 more sources

Five‐Year Trends in Biomarker Testing and Targeted Therapy for NSCLC: A Patient‐Initiated Nationwide Survey in Japan

open access: yesCancer Science, EarlyView.
This nationwide survey reveals that comprehensive multigene testing for advanced NSCLC has rapidly expanded in Japan, steadily increasing the use of targeted therapies for rare oncogenic drivers. Despite these diagnostic advancements, approximately 30% of patients consistently remain untested, highlighting a persistent clinical gap in real‐world ...
Satoshi Ikeda   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy